Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + Carboplatin
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer
Trial Timeline
Jun 30, 2026 → Aug 1, 2027
NCT ID
NCT05403723About Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + Carboplatin
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + Carboplatin is a phase 1 stage product being developed by AstraZeneca for Extensive-stage Small-cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05403723. Target conditions include Extensive-stage Small-cell Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05403723 | Phase 1 | Active |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer